Publication
Co-delivery of two anti-HIV drug nanocrystals from electrospun nanofibers
| Summary: | TRUVADA is the only medication approved by FDA for pre-exposure prophylaxis of the HIV infection. They are tablets with fixed dosages of two antiretroviral compounds for daily oral uptake: Tenofovir disoproxil fumarate (TDF) and Emtricitabine (EMT) that are reverse transcriptase inhibitors. Objectives: Incorporate TDF and EMT drugs in polymeric nanofibers produced by electrospinning; chosen polymers were polyoxyethilene (PEO) and polycaprolactone (PCL). Characterize the nanofibers and study the in vitro release profile of the drugs. Evaluate the possibility of a topical administration of the loaded fibers , by rectal or genital route, for HIV infection prophylaxis. |
|---|---|
| Main Authors: | Malta, Rafaela |
| Other Authors: | Neves, José das; Sarmento, Bruno; Machado, Raul; Lúcio, M.; Viseu, T. M. R. |
| Subject: | HIV infection Tenofovir disoproxil fumarate (TDF) Emtricitabine (EMT) Electrospinning Polymeric nanofibers Controled drug delivery Ciências Médicas::Ciências da Saúde Ciências Médicas::Biotecnologia Médica Ciências Naturais::Ciências Físicas Ciências Naturais::Ciências Químicas Ciências Naturais::Ciências Biológicas Engenharia e Tecnologia::Engenharia Química Engenharia e Tecnologia::Engenharia dos Materiais |
| Year: | 2017 |
| Country: | Portugal |
| Document type: | conference poster |
| Access type: | open access |
| Associated institution: | Universidade do Minho |
| Language: | English |
| Origin: | RepositóriUM - Universidade do Minho |
| Summary: | TRUVADA is the only medication approved by FDA for pre-exposure prophylaxis of the HIV infection. They are tablets with fixed dosages of two antiretroviral compounds for daily oral uptake: Tenofovir disoproxil fumarate (TDF) and Emtricitabine (EMT) that are reverse transcriptase inhibitors. Objectives: Incorporate TDF and EMT drugs in polymeric nanofibers produced by electrospinning; chosen polymers were polyoxyethilene (PEO) and polycaprolactone (PCL). Characterize the nanofibers and study the in vitro release profile of the drugs. Evaluate the possibility of a topical administration of the loaded fibers , by rectal or genital route, for HIV infection prophylaxis. |
|---|